{
    "clinical_study": {
        "@rank": "15143", 
        "acronym": "EXPECT", 
        "arm_group": {
            "arm_group_label": "Endoscopic treatment", 
            "arm_group_type": "Experimental", 
            "description": "Participants undergo upper GI endoscopy with endoscopic mucosal resection (EMR) and/or radiofrequency ablation (RFA) of esophageal squamous dysplasia (ESD).  After initial therapy participants undergo repeat endoscopy every 3 months for a year, with re-biopsy and re-treatment of residual ESD as appropriate."
        }, 
        "brief_summary": {
            "textblock": "Esophageal cancer is common in Kenya. The precursor of esophageal cancer is esophageal\n      squamous dysplasia (ESD).  In this study, persons known to have ESD will undergo endoscopic\n      removal or ablation of ESD in order to prevent development of esophageal cancer."
        }, 
        "brief_title": "Endoscopic Prevention of Esophageal Cancer at Tenwek Hospital", 
        "completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Esophageal Cancer", 
            "Esophageal Squamous Dysplasia"
        ], 
        "condition_browse": {
            "mesh_term": "Esophageal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Esophageal squamous dysplasia (ESD) is the precursor lesion of esophageal squamous cell\n      cancer. ESD causes no symptoms but can be detected by screening.  ESD may harbor various\n      grades of dysplasia.  Patients with moderate grade or high grade dysplasia (MGD or HGD) have\n      up to a 40-fold increased risk of esophageal squamous cell cancer.\n\n      In this study, persons known to have ESD with MGD or HGD on the basis of prior screening\n      will be invited to undergo endoscopic treatment with either endoscopic mucosal resection\n      (EMR) and/or radio frequency ablation (RFA) in order to remove or ablate regions of ESD.\n      Participants will undergo a series of endoscopies to treat ESD and monitor success of\n      treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participant is 18-85 years of age, inclusive\n\n          -  Participant has had a prior endoscopy with Lugol's chromoendoscopy demonstrating an\n             unstained lesion (USL) of at least 5 mm which on biopsy contained moderate grade\n             dysplasia (MGD), high grade dysplasia (HGD), or esophageal squamous cell cancer\n             (ESCC) of flat mucosa limited to the lamina propria, with no evidence of invasion.\n\n          -  The maximum allowable linear length of USL-bearing esophagus is 20 cm.\n\n          -  No more than 14 continuous linear cm of esophagus require treatment for MGD, HGD, or\n             ESCC.\n\n          -  For patients with ESCC, CT scan of chest and upper third of the abdomen shows no\n             exclusionary findings for the trial, such as metastasis.\n\n          -  Participant is not pregnant and has no plans to become pregnant in the ensuing 12\n             months (confirmation of pregnancy status in women of child-bearing age and ability\n             required prior to each endoscopy with urine or blood test, if subject believes she\n             may be pregnant or has missed a menstrual period)\n\n          -  Participant is eligible for treatment and follow-up endoscopy and biopsy as required\n             by the protocol\n\n          -  Participant is willing to provide written, informed consent to participate in this\n             clinical study and understands the responsibilities of trial participation\n\n        Exclusion Criteria:\n\n          -  Esophageal stricture preventing passage of a therapeutic endoscope\n\n          -  Any prior endoscopic resection\n\n          -  Any esophageal dilation in the past 12 months\n\n          -  Any history of ESCC of the esophagus, except for ESCC of flat mucosa limited to the\n             lamina propria diagnosed within 12 months of study enrollment.\n\n          -  In participants with ESCC, any evidence of nodal involvement or distant metastases\n\n          -  Any previous ablative therapy within the esophagus (photodynamic therapy, multipolar\n             electrical coagulation, argon plasma coagulation, laser treatment, or other) or any\n             radiation therapy to the esophagus.\n\n          -  Any previous esophageal surgery, except fundoplication\n\n          -  Evidence of esophageal varices detected within last 6 months or at initial EMR/RFA\n             procedure\n\n          -  Evidence of eosinophilic esophagitis on endoscopy and/or histology\n\n          -  History of coagulopathy, or use of warfarin within the past month.\n\n          -  Report of uncontrolled coagulopathy with international normalized ratio (INR) > 2 or\n             platelet count <75,000 platelets per \u00b5L (note: laboratory testing is not required for\n             all subjects in this study)\n\n          -  Participant is using aspirin, clopidogrel, or non-steroidal anti-inflammatory drugs\n             that cannot be discontinued 7 days before and after therapeutic sessions\n\n          -  Participant has a known history of unresolved drug or alcohol dependency that would\n             limit ability to comprehend or follow instructions related to informed consent,\n             post-treatment instructions, or follow-up guidelines\n\n          -  Participant has an implantable pacing device (examples; automatic implantable\n             cardioverter/defibrillator, neurostimulator, cardiac pacemaker) and has not received\n             clearance for enrollment in this study by the physician responsible for the pacing\n             device\n\n          -  Participant suffers from psychiatric or other illness deemed by the investigator as\n             an inability to comply with protocol\n\n          -  Participant has life expectancy less than 2 years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02146508", 
            "org_study_id": "P62/02/2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Endoscopic treatment", 
                "description": "Endoscopic removal of regions of ESD.", 
                "intervention_name": "Endoscopic Mucosal Resection (EMR)", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Endoscopic treatment", 
                "description": "Endoscopic radiofrequency ablation of regions of ESD", 
                "intervention_name": "Radiofrequency ablation", 
                "intervention_type": "Device", 
                "other_name": [
                    "HALO360 (Covidien, Inc.)", 
                    "HALO90 (Covidien, Inc.)", 
                    "HALO60 (Covidien, Inc.)"
                ]
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Esophageal cancer", 
            "Radiofrequency, catheter ablation", 
            "Endoscopic mucosal resection", 
            "Esophageal squamous dysplasia", 
            "Cancer prevention"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "location": {
            "contact": {
                "email": "research@tenwek.com", 
                "last_name": "Stephen Burgert, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Bomet", 
                    "country": "Kenya", 
                    "zip": "02400"
                }, 
                "name": "Tenwek Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Stephen Burgert, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Russell E White, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Kenya"
        }, 
        "number_of_arms": "1", 
        "official_title": "Endoscopic Prevention of Esophageal Cancer at Tenwek Hospital (The EXPECT Trial) by Removal or Ablation of Esophageal Squamous Cell Dysplasia", 
        "overall_contact": {
            "email": "research@tenwek.com", 
            "last_name": "Stephen L Burgert, MD", 
            "phone": "+254-717971768"
        }, 
        "overall_official": {
            "affiliation": "Tenwek Hospital", 
            "last_name": "Stephen L Burgert, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Kenya: Ethical Review Committee", 
                "Kenya: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The percentage of subjects demonstrating complete response defined as complete histological clearance of MGD, HGD and esophageal squamous carcinoma in the treatment areas at 12 months after the initial ablation procedure.", 
            "measure": "Complete resolution of advanced esophageal squamous dysplasia", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02146508"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Tenwek Hospital", 
            "investigator_full_name": "Stephen Burgert", 
            "investigator_title": "Director of Endoscopy Services", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Percentage of participants experiencing serious adverse events following EMR or RFA treatment.", 
            "measure": "Safety of endoscopic interventions", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "source": "Tenwek Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Mayo Clinic", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "National Cancer Institute (NCI)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Covidien", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Tenwek Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}